# Soligenix Inc. (NASDAQ: SNGX) Proprietary Therapy Shows Promise in Treatment of Psoriasis

* Psoriasis affects approximately 3% of the adult population in the United States, translating to more than 7.5 million individuals.
* By using visible light, Soligenix’s SGX302 aims to mitigate risks while effectively reducing inflammation and promoting skin healing.
* A phase 2a study demonstrated that SGX302 was well tolerated, with no significant adverse events reported.

 Psoriasis is more than just a skin condition — it’s a lifelong autoimmune disorder that disrupts daily life with painful, inflamed patches and an emotional toll that can be just as severe as the physical symptoms. Soligenix (NASDAQ: SNGX) is at the forefront of developing innovative therapies for this condition, notably SGX302 (synthetic hypericin), a novel treatment currently undergoing Phase 2a clinical trials aimed at addressing mild to moderate psoriasis.

 Psoriasis affects approximately 3% of the adult population aged 20 years or older in the United States, translating to more than 7.5 million individuals. Notably, around 600,000 adults in the United States live with undiagnosed psoriasis. The prevalence is similar between males (2.8%) and…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireSan Francisco, CAwww.BioMedWire.com415.949.5050 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/soligenix-inc-nasdaq-sngx-proprietary-therapy-shows-promise-in-treatment-of-psoriasis/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/soligenix-s-sgx302-offers-new-hope-for-psoriasis-patients/448fdae7805466ab9f24fece27f1179b) 

 



[Reddit Post](https://www.reddit.com/r/Business_NewsRamp/comments/1ler56g/soligenixs_sgx302_offers_new_hope_for_psoriasis/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/256/18/dashsK9O.webp)